Avicursen

N/A

Report date: 2025/05/23 14:38:43
NME

Base Information

Drug NameAvicursen
Drug Alias NameISIS-107248ATL/TV-1102ATL-1102TV-1102
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionIntegrin alpha-4 antagonistsIntegrin alpha-4/beta-1 antagonists
TargetsIntegrin alpha-4/beta-1Integrin alpha-4
Therapy Area/IndicationsMultiple SclerosisMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaSlovakia +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAntisense Therapeutics
Inactive CompaniesPercheron Therapeutics Ltd
Active IndicationsMultiple Sclerosis
Inactive IndicationsMuscular Dystrophy, Duchenne

Other Information

ATC CodeN/A
Related LinksN/A